NVCT - Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement
NVCT - Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Story updates
11:31:33 AM UTC
SquawkNews
NVCT ciprocopan (nxp100) receives marketing approval in China for the treatment of patients with pnh previously untreated with complement inhibitors Nuvectis Pharma - ciprocopan (nxp100) receives marketing approval in China for treatment-naive pnh patients
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.